Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide vs Hydroxyurea in Essential Thrombocythaemia
NCT01065038Phase 3Completed
- Sponsor
- AOP Health
- Start
- Sep 2002
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of anagrelide in essential thrombocythemia (ET), sponsored by AOP Health. Started Sep 2002; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01065038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01065038.